Linkage of a candidate gene locus to familial combined hyperlipidemia - Lecithin: Cholesterol acyltransferase on 16q

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 11, 1999, Pages 2730-2736

  Aouizerat, Bradley E ^a   Allayee, Hooman ^a   Cantor, Rita M ^b   Dallinga Thie, Geesje M ^c   Lanning, Christopher D ^b   De Bruin, Tjerk W A ^d   Lusis, Aidons J ^a,e   Rotter, Jerome I ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Familial combined hyperlipidemia; Genetics; Lecithin:cholesterol acyltransferase; Lipid metabolism

Indexed keywords

CHOLESTEROL; MANGANESE SUPEROXIDE DISMUTASE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHROMOSOME 16Q; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; GENE LOCUS; GENETIC LINKAGE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL; QUANTITATIVE TRAIT;

ADULT; AGED; ALLELES; APOLIPOPROTEIN A-I; APOLIPOPROTEIN C-III; APOLIPOPROTEINS A; APOLIPOPROTEINS C; CHROMOSOMES, HUMAN, PAIR 16; FAMILY HEALTH; FEMALE; GENE EXPRESSION; GENETIC MARKERS; HAPLOTYPES; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; LINKAGE (GENETICS); MALE; MIDDLE AGED; NUCLEAR FAMILY; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; SUPEROXIDE DISMUTASE;

EID: 0032698344     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.11.2730     Document Type: Article

References (49)

1. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary artery disease, II: genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973;52:1544-1568.
2. Rose HG, Kranz P, Weinstock M, Juliano J, Haft JI. Inheritance of combined hyperlipoproteinemia: evidence for a new lipoprotein phenotype. Am J Med. 1973;54:148-160.
3. Brunzell JD, Albers JJ, Chait A, Grundy SM, Groszek E, McDonald GB. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res. 1983;24:147-155.
4. Babirak SP, Brown G, Brunzell JD. Familial combined hyperlipidemia and abnormal lipoprotein lipase. Arterioscler Thromb. 1992;12: 1176-1183.
5. Castro Cabezas M, de Bruin TWA, Erkelens DW. Familial combined hyperlipidemia: 1973-1991. Neth J Med. 1992;40:83-95.
6. Kwiterovich PO. Genetic and molecular biology of familial combined hyperlipidemia. Curr Opin Lipidol. 1993;4:133-143.
7. Lusis AJ, Ivandic B. Lipid metabolism. In: Rimoin DL, Conner JM, Pyeriz RE, eds. Principles and Practice of Medical Genetics. New York: Churchill Livingston; 1997:1945-1976.
8. Nikkila EA, Aro A. Family study of serum lipids and lipoproteins in coronary heart disease. Lancet. 1973; 1:954-959.
9. Glueck CJ, Fallal R, Buncher CR, Tsang R, Steiner P. Familial combined hyperlipoproteinemia: studies in 91 adults and 95 children from 33 kindred. Metabolism. 1973;23:1403-1428.
10. Williams WR, Lalouel JM. Complex segregation analysis of hyperlipidemia in a Seattle sample. Hum Hered. 1982;32:24-26.
11. Cullen P, Farren B, Scott J, Farrall M. Complex segregation analysis provides evidence for a major gene acting on serum triglyceride levels in 55 British families with familial combined hyperlipidemia. Arterioscler Thromb. 1994;14:1233-1249.
12. Jarvik GP, Brunzell JD, Austin MA, Krauss RM, Motulsky AG, Wijsman E. Genetic predictors of FCHL in four large pedigrees: influence of apoB level major locus predicted genotype and LDL subclass phenotype. Arterioscler Thromb. 1994;14:1687-1694.
13. Porkaa KVK, Nuotio I, Pajukanta P, Ehnholm C, Suurinkeroinen L, Syvanen M, Lehtimaki T, Lahdenkari AT, Lahdenpera S, Ylitalo K, Antikainen M, Perola M, Raitakari OT, Kovanen P, Viikari JSA, Peltonen L, Taskinen MR. Phenotype expression in familial combined hyperlipidemia. Atherosclerosis. 1997;133:245-253.
14. Bredie SJH, Kiemeney LA, de Haan AFJ, Demacker PMN, Stalenhoef AFH. Inherited susceptibility determines the distribution of dense lowdensity lipoprotein subfraction profiles in familial combined hyperlipidemia. Am J Hum Genet. 1996;58:812-822.
15. Allayee H, Aouizerat BE, Cantor RM, Dallinga-Thie GM, Krauss RM, Lanning CD, Rotter JI, Lusis AJ, de Bruin TWA. Families with familial combined hyperlipidemia and families enriched for coronary artery disease share genetic determinants for the atherogenic lipoprotein phenotype. Am J Hum Genet. 1998;63:577-585.
16. Aitman TJ, Godsland IF, Farren B, Crook D, Wong HJ, Scott J. Defects of insulin action on fatty acid and carbohydrate metabolism in familial combined hyperlipidemia. Arterioscler Thromb VascBiol. 1997;17:748-754.
17. Castro Cabezas M, de Bruin TWA, de Valk HW, Shoulders CC, Jansen H, Erkelens DW. Impaired fatty acid metabolism in familial combined hyperlipidemia: a mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J Clin Invest. 1993;92:160-168.
18. Grundy SM, Chait A, Brunzell JD. Familial combined hyperlipidemia workshop. Arteriosclerosis. 1987;7:203-207.
19. Chait A, Albers JJ, Brunzell JD. Very low density lipoprotein overproduction in genetic forms of hypertriglyceridemia. Eur J Clin Invest. 1980;110:12-22.
20. Janus ED, Nicoll AM, Turner PR, Magill P, Lewis B. Kinetic bases of the primary hyperlipidemias: studies of apolipoprotein B turnover in genetically defined subjects. Eur J Clin Invest. 1980;10:161-172.
21. Kissebah AH, Alfarsi S, Adams PW. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein B kinetics in man: normolipidemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia. Metabolism. 1981;30:856-868.
22. Conner TA, Coates PM, Bennett MJ, Cryer DR, Le N-A. Familial combined hyperlipidemia: use of stable isotopes to demonstrate overproduction of very low density apolipoprotein B by the liver. J Inherit Metab Dis. 1991;14:915-922.
23. Venkatesan S, Cullen P, Pacy P, Halliday D, Scott J. Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arterioscler Thromb. 1993;13:1110-1118.
24. Nevin DN, Brunzell JD, Deeb SS. The LPL gene in individuals with familial combined hyperlipidemia and decreased LPL activity. Arterioscler Thromb. 1994;14:869-873.
25. Gagne E, Genest J, Zang H, Clarke LA, Hayden MR. Analysis of DNA changes in the LPL gene in patients with familial combined hyperlipidemia. Arterioscler Thromb. 1994;14:1250-1257.
26. Reymer PW, Groenemeyer BE, Gagne E, Miao L, Appelman EE, Seidel JC, Kromhout D, Bijvoet SM, van de Oever K, de Bruin TWA. A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) contributes to the expression of familial combined hyperlipidemia. Hum Mol Genet. 1995;4:1543-1549.
27. Deeb SS, Nevin DN, Iwasaki L, Brunzell JD. Two novel apolipoprotein A-IV variants in individuals with familial combined hyperlipidemia and diminished levels of lipoprotein lipase activity. Hwn Mutat. 1996;8:319-325.
28. Yang WS, Nevin DN, Peng R, Brunzell JD, Deeb SS. A mutation in the promoter of the lipoprotein lipase (LPL) gene in a patient with familial combined hyperlipidemia and low LPL activity. Proc Natl Acad Sci USA. 1995;92:4462-4466.
29. Hoffer MJ, Bredie SJ, Boomsma DI, Reymer PW, Kastelein JJ, de Knijff P, Demacker PN, Stalenhoef AF, Havekes LM, Frants RR. The lipoprotein lipase (Asn291Ser) mutation is associated with elevated lipid levels in families with familial combined hyperlipidemia. Atherosclerosis. 1996;119:159-167.
30. Mailly F, Tugrul Y, Reyme PW, Bruin T, Seed M, Groenemeyer BF, Asplund-Carlson A, Vallance D, Winder AF, Miller GJ. A common variant in the gene for lipoprotein lipase (Asp9Asn): functional implications and prevalence in normal and hyperlipidemic subjects. Arterioscler Thromb Vasc Biol. 1995;15:468-478.
31. Castro Cabezas M, de Bruin TWA, Jansen H, Kock LAW, Kortland W, Erkelens DW. Impaired chylomicron remnant clearance in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 1993;13:804-814.
32. Dallinga-Thie GM, van Linde-Sibenius Trip M, Rotter JI, Cantor RM, Bu XD, Lusis AJ, de Bruin TWA. Complex genetic contribution of the apoAI-CIII-AIV gene cluster to familial combined hyperlipidemia. J Clin Invest. 1997;99:953-961.
33. Dallinga-Thie GM, Bu XD, van Linde-Sibenius Trip M, Rotter JI, Lusis AJ, de Bruin TWA. Apolipoprotein AI-CIII-AIV gene cluster in familial combined hyperlipidemia: effects on LDL-cholesterol and apolipoproteins B and C-III. J Lipid Res. 1996;37:136-147.
34. Wojciechowski AP, Farrall M, Cullen P, Wilson TM, Bayliss JD, Farren B, Griffin BA, Caslake MJ, Packard CJ, Shepard J. Familial combined hyperlipidemia linked to the apolipoprotein AI-CIII-AIV gene cluster on chromosome IIq23-q24. Nature. 1991;349:161-164.
35. de Bruin TWA, Mailly F, van Barlingen HJJ, Fisher R, Castro Cabezas M, Talmud P, Dallinga-Thie GM, Humphries SE. Lipoprotein lipase gene mutations D9N and N291S in four pedigrees with familial combined hyperlipidemia. Eur J Clin Invest. 1996;26:631-639.
36. Coresh J, Beaty TH, Kwiterovich PO Jr, Antonarakis SE. Pedigree and sib-pair linkage analysis suggest the apolipoprotein B gene is not the major gene influencing plasma apolipoprotein B levels. Am J Hum Genet. 1992;50:1038-1045.
37. Pajukanta P, Porkka KV, Antikainen M, Taskinen MR, Perola M, Murtomaki-Repo S, Ehnholm S, Nuotio I, Suurinkeroinen L, Lahdenkari AT, Syvanen AC, Viikari JS, Ehnholm C, Peltonen L. No evidence of linkage between familial combined hyperlipidemia and genes encoding lipolytic enzymes in Finnish families. Arterioscler Thromb Vasc Biol. 1997;17:841-850.
38. Aguilar-Salinas CA, Hugh P, Barret R, Pulai J, Zhu XL, Schonfeld G. A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism: kinetics of apolipoprotein B during placebo and pravastatin therapy. Arterioscler Thromb Vasc Biol. 1997;17:72-82.
39. Zuliani G, Hobbs HH. Tetranucleotide repeat polymorphism in the apolipoprotein CIII gene. Nucleic Acids Res. 1990;18:4299.
40. Weber JL, May PE. Abundant class of human DNA polymorphisms which can be typed using polymerase chain reaction. Am J Hum Genet. 1989;44:388-96.
41. Cooperative Human Linkage Center. Available at: http://www.chlc.org. Accessed November 1998.
42. Whitehead Institute for Biomedical Research. Available at: http://www.genome.wi.mit.edu. Accessed November 1998.
43. Beckman JS, Tomfohrde T, Barnes RI, Williams M, Broux O, Richard I, Weissenbach J, Bowcock AM. A linkage map of human chromosome 15 with an average resolution of 2 cM and containing 55 polymorphic microsatellites. Hum Mol Genet. 1993;2:2109-2130.
44. Zuliani G, Hobbs HH. Dinucleotide repeat polymorphism at the 3′ end of the LDL receptor gene. Nucleic Acids Res. 1990;18:4300.
45. The Genome Database. Available at: http://gdbwww.gdb.org. Accessed November 1998.
46. Sharp D, Ricci B, Kienzle B, Lin MC, Wetterau JR. Human microsomal triglyceride transfer protein large subunit gene structure. Biochemistry. 1994;33:9057-9061.
47. Jokinen E, Sakai J, Yamamoto T, Hobbs HH. CGG triple repeat polymorphism in the VLDL receptor (VLDLR) gene. Hum Mol Genet. 1994;3:521.
48. Sakai N, Yamashita S, Hirano K, Menju M, Arai T, Kobayashi K, Ishigama M, Yoshida Y, Hoshino T, Nakajima N, Kameda-Takemura K, Matsuzawa Y. Frequency of exon 15 missense mutation (442D:G) in cholesteryl ester transfer protein gene in hyperalphalipoproteinemic Japanese subjects. Atherosclerosis. 1995;114:139-145.
49. Skretting G, Prydz H. An amino acid exchange in exon I of the human lecithin:cholesterol acyltransferase (LCAT) gene is associated with fish eye disease. Biochem Biophys Res Commun. 1992;182:583-587.